CN100360523C - 1,2,4 furodazole-phenoxyalkyl substituted derivative of iso-oxazole, preparation method and anti virus application - Google Patents
1,2,4 furodazole-phenoxyalkyl substituted derivative of iso-oxazole, preparation method and anti virus application Download PDFInfo
- Publication number
- CN100360523C CN100360523C CNB200510039135XA CN200510039135A CN100360523C CN 100360523 C CN100360523 C CN 100360523C CN B200510039135X A CNB200510039135X A CN B200510039135XA CN 200510039135 A CN200510039135 A CN 200510039135A CN 100360523 C CN100360523 C CN 100360523C
- Authority
- CN
- China
- Prior art keywords
- alkyl
- acid
- group
- isoxazole
- piperazine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
The present invention relates to a compound of which the structural formula is disclosed as I, salt which can be accepted by the pharmacy, a preparation method of, and the application thereof in preparation of medicine for curing picornavirus infection.
Description
Technical field
The present invention relates to 1,2 of novelty, 4-oxadiazole-benzene oxyalkyl replaces De Isoxazole derivative, its preparation method and their application in the medicine that preparation treatment picornavirus infects.
Background technology
Flu is one of world's disease the most common, that social life is had the greatest impact.In the U.S., there is every year people to suffer from acute respiratory disease at least one time above 85%.The adult suffers from flu every year on average 2-3 time, and the preprimary child suffers from 3-7 time every year on average.Early stage in the nineties, the OTC medication cost that is used to extenuate cold symptoms every year is 2,000,000,000 dollars.And can't estimate especially to the loss that society brings because of flu rest cisco unity malfunction.And upper respiratory tract infection such as flu are the common causes of microbiotic abuse, and this has not only increased unnecessary medical expense, also can cause the continuous increase of resistant organism.
(human rhinoviruses is a kind of picornavirus HRVs) to ERC group virus, and more than 100 kind of blood serum subtype arranged.It is reported that grownup and children's common cold has more than 50% by ERC group virus and causes (is not that picornavirus causes though also have about 1/3 flu); Simultaneously, ERC group virus can also cause acute otitis media, sinusitis paranasal sinusitis, and causes deterioration of asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD) and cystic fibrosis etc.For some special crowds such as old man, children and immunocompromised person, be subjected to serious HRVs especially easily and infect.
In three more than ten years in the past, people have carried out research extensively and profoundly to HRVs, synthesized the different compound of a large amount of structures and mechanism of action, but most compounds is eliminated for various reasons after the research that compares extensively and profoundly, progress is slow.
The Diana of U.S. Sterling Winthrop Inc. etc. has synthesized 1,2 of a large amount of structural formula II, 4-oxadiazole-benzene oxyalkyl replace the De Isoxazole derivative [referring to Diana etc., J.Med.Chem., 28:1906-15 (1985); The same, 31:540-544 (1988); 35:1002-1008 (1992); 4628-4633 (1992); 36:3240-50 (1993); 37:2421-36 (1994); 38:1355-71 (1995)], in the structural formula: R1 can be alkyl, alkoxyl group, hydroxyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl or hydroxyl alkoxyl group, alkane
Sulfane base, alkyl sulfenyl alkyl, alkyl sulfonyl alkyl, aminoalkyl group, alkyl-substituted amino alkyl, dialkyl group substituted-amino alkyl, alkoxycarbonyl, carboxyl or nitrile methyl;
R
2And R
3Be respectively hydrogen, alkyl, alkoxyl group, halogen, cyano group, trifluoromethyl and nitro;
R
4Be alkyl, alkoxyl group, hydroxyl, monochloromethyl, dihalomethyl, trihalogenmethyl, two haloethyls, cycloalkyl, heterocycle, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, alkyl carboxylic oxyalkyl, cyano group, halogen, alkylthio, alkane sulfane base, alkylthio, sulfydryl, 2,2,2-trifluoroethyl, (4-methyl-phenyl) sulphonyl oxygen methyl, amino, alkyl-substituted amino, dialkyl group substituted-amino, amido, N-alkyl replace amido etc.;
R
5Be hydrogen, halogen or alkyl;
R
6Be ester group or its bioisostere such as the heterocycles such as oxazoline Huan, oxadiazole ring, tetrazole that can be hydrolyzed into carboxylic acid;
X is O, S etc.;
Z is the saturated carbon chains of 1-9 carbon atom.
This compounds is through research repeatedly for many years, in 2002, the Pleconaril (structural formula II I) of U.S. Viro Pharma and the joint research exploitation of AventisPharmaceuticals company formally submits application for registration to U.S. FDA, and this is the medicine [Scrip No2666:21 (2001)] that first application is used for the ERC group virus respiratory tract infection.Unfortunately, this compound fails to ratify listing on schedule, except replenishing because of needs the drug interaction data of this compound and other drug such as NSAID (non-steroidal anti-inflammatory drug) or contraceptive bian, allegedly also not ideal to the time that shortens cold symptoms, have only [Scrip No2731:20 (2002)] about 1 day; This is to a research huge strike beyond doubt in this field, but, thereby if having the anti-ERC group virus effect of new compound stronger than Pleconaril, to alleviating the more Zao recovery of the faster patient of making of cold symptoms, for example, cold symptoms shortens 2 days, 3 days or more for a long time, then may become first new rhinovirus medicine and be subjected to welcoming widely.
Summary of the invention
The object of the present invention is to provide a class new have 1,2 of a pharmaceutical use, 4-oxadiazole-benzene oxyalkyl replaces the De Isoxazole derivative.
It is a kind of 1,2 that another object of the present invention provides, and 4-oxadiazole-benzene oxyalkyl replaces the preparation method of De Isoxazole derivative.
Further aim of the present invention provides the application of above-claimed cpd in the medicine that preparation treatment picornavirus infects.
For this reason, the invention provides the new compound of structural formula I:
In the structural formula:
R
1Be alkyl, alkoxyl group, hydroxyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl, hydroxyl alkoxyl group, alkane sulfane base, alkyl sulfenyl alkyl, alkyl sulfonyl alkyl, aminoalkyl group, alkyl-substituted amino alkyl, dialkyl group substituted-amino alkyl, alkoxycarbonyl, carboxyl or nitrile methyl;
R
2And R
3Be respectively hydrogen, alkyl, alkoxyl group, halogen, cyano group, trifluoromethyl or nitro;
R
4Be alkyl, alkoxyl group, hydroxyl, monochloromethyl, dihalomethyl, trihalogenmethyl, two haloethyls, cycloalkyl, heterocycle, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, alkyl carboxylic oxyalkyl, cyano group, halogen, alkylthio, alkane sulfane base, alkylthio, sulfydryl, 2,2,2-trifluoroethyl, (4-methyl-phenyl) sulphonyl oxygen methyl, amino, alkyl-substituted amino, dialkyl group substituted-amino, amido or N-alkyl replace amido;
R
5Be hydrogen, halogen or alkyl;
X is O or S;
Y is oxygen, sulphur or NR
6, the R here
6Being alkyl, acyl group, aralkyl, aroyl, alkylsulfonyl, also can be ring-type heterocycle such as pyrroles, pyridine, imidazoles and hydrogenation heterocycle such as tetramethyleneimine, imidazolidine, piperidines, piperazine, morpholine;
N is 0-5;
M is 0-5.
The concrete selection,
R
1Be C
1-5Alkyl such as methyl, ethyl, propyl group, sec.-propyl, cyclopropyl, hydroxyl-C
1-5Alkyl, C
1-3Alkoxy-C
1-5Alkyl, first thiomethyl, methyl sulfinyl methyl, methylsulfonyl methyl, amino-C
1-5Alkyl, C
1-3Alkylamino-C
1-5Alkyl, C
1-3Dialkyl amido-C
1-5Alkyl, C
1-5Alkoxycarbonyl, carboxyl or cyanogen methyl.
R
2And R
3Be respectively C
1-5Alkyl such as methyl, halogen such as chlorine, bromine, fluorine, cyano group, trifluoromethyl or nitro.
R
4Be C
1-3Alkyl such as methyl, ethyl, propyl group, sec.-propyl, tertiary butyl, cyclopropyl, trihalogenmethyl such as trichloromethyl or trifluoromethyl.
R
5Be hydrogen, halogen or C
1-5Alkyl.
X is O.
Y is oxygen, sulphur or NR
6, the R here
6Be C
1-8Alkyl, acyl group, benzyl, aroyl, alkylsulfonyl also can be ring-type heterocycle such as pyrroles, pyridine, imidazoles and hydrogenation heterocycle such as tetramethyleneimine, imidazolidine, piperidines, piperazine, morpholine.
M is 1-3;
N is 1-3.
The preparation of these compounds is example (structural formula IA) with the X=O among the structural formula I,
R
1, R
2And R
3, R
4, m and n definition the same.
The preparation method of Compound I A is as follows: earlier synthetic benzene oxyalkyl replaces De isoxazole intermediate xi, then with 1,2, the precursor cyano group of 4-oxadiazole ring is converted into 1,2,4-oxadiazole ring, last and suitable carboxylic acid salify, these acid can be mineral acid example hydrochloric acid, Hydrogen bromide, hydroiodic acid HI, sulfuric acid, phosphoric acid, nitric acid; Also can be organic acid, as saturated fatty acid, the C of 1～10 carbon atom
1-4The unsaturated fatty acids of alkylsulphonic acid, 4～20 carbon atoms, substituted carboxylic acid, aromatic acid and replacement aromatic acid are as formic acid, acetate, propionic acid, butyric acid, valeric acid, caproic acid, fumaric acid, toxilic acid, succsinic acid, tartrate, phenylformic acid, picric acid, Phenylsulfonic acid, tosic acid.
R
1, R
2And R
3, R
4, m and n definition the same.
The preparation method of intermediate xi can be: substituted phenol iv bromination obtains bromophenol v, bromophenol v and cuprous cyanide reaction obtain cyanophenol vi, cyanophenol vi obtains intermediate viii through alkylation reaction etherificate, amination reaction, obtains xi with replacement De isoxazole x reaction again; Reaction formula is as follows:
R
1, R
2, R
3The same with the definition of m and n.
Intermediate xi also can prepare by the following method.
R
1, R
2And R
3, m and n definition the same.
Biological study
The new compound of preparation has carried out the biological assessment of antipicornaviral, the test virus strain is the ERC group virus N32 (virus strain of being separated alone and being identified by Nanjing Medical University microorganism and immunology teaching and research room, in the human kidney cells preservation of going down to posterity), test design is established blank and positive controls, and the positive control medicine uses laboratory synthetic Pleconaril.Biological evaluation result is as follows:
The concentration (μ g/ml) of external effective inhibition rhinovirus N32 strain and with the specific activity of positive drug Pleconaril
| Compound | Medicine is handled cell monolayer earlier and is added rhinovirus after 24 hours | Medicine and rhinovirus add cell monolayer simultaneously | Medicine adds and adds the cell individual layer after 4 ℃ of rhinoviruss spend the night | |||
| Concentration | With compare | Concentration | With compare | Concentration | With compare | |
| Positive control drug Pleconaril | 12.5 | 1 | 6.25 | 1 | 25～50 | 1 |
| IA 1 | 1.56 | 8 | 1.56 | 4 | 3.125 | 8 |
| IA 2 | 0.39 | 32 | 0.78 | 16 | 0.78 | 32 |
| IA 3 | 0.39 | 32 | 0.39 | 16 | 0.39 | 64 |
| IA 4 | 0.20 | 62.5 | 0.39 | 16 | 0.39 | 64 |
| IA 5 | 0.20 | 62.5 | 039 | 16 | 3.125 | 8 |
| IA 6 | 0.78 | 16 | 0.39 | 16 | 1.56 | 16 |
Preliminary pharmacodynamics The selection result proves that compound in structural formula I provided by the invention has the antipicornaviral activity stronger than Pleconaril, therefore has the treatment picornavirus and infects, particularly the application prospect of rhinovirus infection.
Specific implementation method
Embodiment 1
(1), 2,6-dimethyl-right-bromophenol (v, R
2=R
3=CH
3)
With 2,6-xylenol (iv, R
2=R
3=CH
3, 61g 0.5mol) is dissolved in the 125ml Glacial acetic acid, when temperature is lower than 10 ℃, drip be dissolved with bromine (25.7ml, 125ml glacial acetic acid solution 0.5mol) drips, reaction solution is poured in 650ml 1% sodium sulfite solution, filtered, get white powder solid 95.2g.Get white needle-like crystals 85.3g, yield 84.8%, mp78.4-78.7 ℃ with sherwood oil (60-90 ℃) recrystallization.(2), 4-hydroxyl-3,5-dimethyl benzene nitrile (vi, R
2=R
3=CH
3)
With v (R
2=R
3=CH
3, 40.2g, 0.2mol), cuprous cyanide (20.6g, 0.23mol) and DMF30ml add reaction flask, stirring and refluxing 5 hours.Reaction finishes, and is chilled to room temperature, reaction solution is poured into 80g six Ferric Chloride Hydrateds that prepare in advance, the mixing solutions of 20ml concentrated hydrochloric acid and 120ml water filters, and filter cake is with after washing in right amount, use dissolve with ethanol, elimination impurity concentrates, with excessive sodium hydrate solution heating for dissolving, decolouring is filtered, in filtrate, drip dilute hydrochloric acid, till not having solid to occur, filter, get pale powder shape solid 18.5g, yield 62.7%, mp123-124 ℃.
(3), 4-(2-bromine oxethyl)-3,5-dimethyl benzene nitrile (vii, R
2=R
3=CH
3, m=2)
With vi (R
2=R
3=CH
3, 7.36g, 0.05mol), (34.5mol 0.4mol) is dissolved in the 500ml acetone glycol dibromide, add fine ground Anhydrous potassium carbonate (16.6g, 0.1mol), mechanical stirring back flow reaction 24h, filtered while hot, concentrate column chromatography [sherwood oil (60-90 ℃): ethyl acetate=10: 1 (v: v)], get white cotton-shaped solid 10.4g, yield 81.85%, mp79.9-80.8 ℃.
(4), 3,5-dimethyl-4-(2-(piperazine-1-yl) oxyethyl group) benzene nitrile (viii, R
2=R
3=CH
3, m=2)
With Piperazine anhydrous (8.01g 0.093mol) adds and to be equipped with in the 100ml eggplant-shape bottle of reflux condensing tube, adds 35ml toluene, after the heated and stirred dissolving, backflow 15min.Be chilled to about 50 ℃, drip vii (R
2=R
3=CH
3, m=2,2.54g, toluene solution 15ml 0.01mol).After dripping, be warming up to backflow, reaction 2h.Cooling has solid to separate out (therefrom reclaiming piperazine 2.5g), and inclining toluene solution, (3 * 30ml) extractions merge water, add 10% sodium hydroxide solution with 1N dilute hydrochloric acid, the adularescent precipitation generates, and adding to does not have till the precipitation generation, with ether (3 * 50ml) extractions, merge organic phase, water and saturated common salt washing, anhydrous sodium sulfate drying, concentrate, get white waxy solid 2.1g, productive rate 81.0%, mp51.4-52.2 ℃.
ESI-MS：260[M+H]
+
(5), 5-(3-chloropropyl)-3-methyl-isoxazole (x, R
1=CH
3, n=3)
Be equipped with in the 500ml four-necked bottle of mechanical stirring, dropping funnel, thermometer and reflux condensing tube one, adding NCS (12.02g, the dry DMF solution of 144ml 0.09mol) adds 1-2 again and drips pyridine, drip ethylidenehydroxylamine (5.5ml, the dry DMF solution of 36ml 0.09mol) under the room temperature.Drip and finish, keep 25-30 ℃ of reaction 1h.Add 5-chloro-1-pentyne (ix, R then
1=CH
3, n=3,5.3ml, the dry DMF solution of 40ml 0.05mol) is warming up to 85-90 ℃, and (12.5ml, the dry DMF solution of 72ml 0.09mol) keep 85-90 ℃ of reaction 1.5h to drip triethylamine.After reaction finishes, be chilled to room temperature, add 100ml water, with ethyl acetate (3 * 300ml) extractions merge organic phase, use 10% sal enixum, water, each 150ml of saturated aqueous common salt washes, anhydrous magnesium sulfate drying is concentrated.Underpressure distillation, the cut of collection 109-113 ℃ (5mmHg) gets light yellow liquid 5.45g, productive rate 68.34%.
(6), 3,5-dimethyl-4-[2-[4-[3-(3-methyl-isoxazole-5-yl) propyl group] piperazine-1-yl] oxyethyl group] benzene nitrile (xi, R
1=R
2=R
3=CH
3, m=2, n=3)
Be equipped with in the 250ml eggplant-shape bottle of reflux condensing tube and drying tube one, add viii (R
2=R
3=CH
3, m=2,7.78g, 0.03mol), x (R
1=CH
3, n=3,5.26g, 0.033mol), Anhydrous potassium carbonate (8.29g, 0.06mol), potassiumiodide (9.96g, 0.06mol) and 120ml DMF, 80 ℃ of stirring reaction 5h.Reaction is chilled to room temperature after finishing, and adds 100ml water, and (3 * 100ml) extractions merge organic phase, wash with water, concentrate, and add excessive dilute hydrochloric acid, stir 1-2h with ethyl acetate.(2 * 100ml) extractions add sodium hydroxide solution to aqueous phase again, and the adularescent precipitation generates with ethyl acetate, add to and do not have the precipitation generation, (3 * 100ml) extractions merge organic phase, water with ethyl acetate, the saturated common salt washing, anhydrous sodium sulfate drying concentrates, and gets off-white powder shape solid (8.8g, 76.79%), is not further purified and promptly drops into the next step.
ESI-MS：383[M+H]
+
(7), N '-hydroxyl-3,5-dimethyl-4-[2-[4-[3-(3-methyl-isoxazole-5-yl) propyl group] piperazine-1-yl] oxyethyl group] benzenyl amidine (xii, R1=R
2=R
3=CH
3, m=2, n=3)
In the 100ml eggplant-shape bottle, add xi (R
1=R
2=R
3=CH
3, m=2, n=3,2.35g, 0.0062mol), (2.14g, 0.03mol), (4.25g 0.03mol) with dehydrated alcohol 30ml, refluxes and stirs 18h Anhydrous potassium carbonate oxammonium hydrochloride.After reaction finished, filtered while hot with an amount of hot absolute ethanol washing, concentrated filtrate, gets yellow syrupy shape solid.Add the 50ml ethyl acetate, have cotton-shaped solid insoluble, filter, filtrate concentrates, column chromatography [chloroform: methyl alcohol=10: 1 (v: v)], get yellow powder powder solid 1.4g, productive rate 54.41%, mp128.7-130.2 ℃.
ESI-MS：416[M+H]
+
(8), 1-[2-[2,6-dimethyl-4-(5-Trifluoromethyl-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-methyl-isoxazole-5-yl) propyl group] piperazine hydrochloride (IA
1, R
1=R
2=R
3=CH
3, m=2, n=3, R
4=CF
3)
With xii (R
1=R
2=R
3=CH
3, m=2, n=3,0.21g 0.0005mol) adds in the 25ml three-necked bottle with the 4ml dry pyridine, after the stirring at room dissolving, the dropping trifluoroacetic anhydride (0.14ml, 0.001mol).Finish, continue to stir 15min.Then be warming up to backflow, reaction 1h.Be chilled to room temperature, in ten times of amounts of reaction solution impouring frozen water, have solid to separate out and stick on the wall.Inclining solution, transfers PH to alkalescence with dilute NaOH solution, concentrates.In enriched product, add entry 20ml, use chloroform extraction (3 * 20ml) again.The solid of separating out is dissolved with the 20ml chloroform, and combined chloroform liquid with saturated aqueous common salt and washing, drying, concentrates, column chromatography [chloroform: acetone=4: 1 (v: v)], get light brown oily thing, put in the refrigerator and solidify.It is dissolved in 2ml acetone, feeds excess chlorination hydrogen, have solid to separate out, filter, the dehydrated alcohol recrystallization gets off-white powder shape solid, and yield is 67.1%, mp209-210 ℃.
IR(KCl，cm
-1)：3408，2976，2377，1608，1470，1417，1378，1321，1206，1156，1110，993，770；
ESI-MS：494[M+H]
+；
1HNMR (300MHz D
2O) δ (ppm): 2.07～2.21 (m, 2H ， isoxazole ring-C-CH
2-), 2.18 (s, 3H ， isoxazole ring 3-CH
3), 2.28 (s, 6H, 2 * Ar-CH
3), 2.83 (t, 2H, J=7.2Hz ， isoxazole ring-C-C-CH
2-piperazine ring), 3.28 (t, 2H, J=8.1Hz ， isoxazole ring-CH
2-), 3.66 (br, 10H, 8 H on the piperazine ring and piperazine ring-CH
2-C-O-Ar), 4.20 (br, 2H ,-CH
2-O-Ar), 6.09 (s, 1H ， isoxazole ring 4-H), 7.69 (s, 2H, 2 * Ar-H);
Anal.C
24H
30N
5O
3F
3·2HCl Found(％)：C 50.81，H 5.66，N 12.20
Calcd(％)：C 50.89，H 5.69，N 12.36
Embodiment 2
1-[2-[2,6-dimethyl-4-(5-methyl isophthalic acid, 2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-methyl-isoxazole-5-yl) propyl group] piperazine hydrochloride (IA
3, R
1=R
2=R
3=R
4=CH
3, m=2, n=3)
With reference to IA
1(R
1=R
2=R
3=CH
3, m=2, n=3, R
4=CF
3) the preparation method by xii (R
1=R
2=R
3=CH
3, m=2, n=3,0.62g, 0.0015mol) and Acetyl Chloride 98Min. (0.l9ml 0.0023mol) makes.Column chromatography [chloroform: acetone=4: 1 (v: v)], get faint yellow oily thing,
1HNMR (300MHz, CDCl
3), δ (ppm): 1.85～1.90 (m, 2H ， isoxazole ring-C-CH
2-C-piperazine ring), 2.26 (s, 3H ， isoxazole ring 3-CH
3), 2.34 (s, 6H, 2 * Ar-CH
3), 2.41 (t, 2H, J=7.5Hz ， isoxazole ring-C-C-CH
2-piperazine ring) 2.54～2.63 (8 H on the piperazine ring are with oxadiazole ring-CH for br, 11H
3), 2.75 (t, 2H, J=7.5Hz ， isoxazole ring-CH
2-C-C-piperazine ring), 2.82 (t, 2H, J=6Hz, piperazine ring-CH
2-C-O-Ar), 3.94 (t, 2H, J=5.9Hz ,-CH
2-O-Ar), 5.8l (s, 1H ， isoxazole ring 4-H), 7.72 (s, 2H, 2 * Ar-H); Salify gets the white plates crystal, and yield is 72.9%, mp223-225 ℃.
IR(KCl，cm
-1)：2974，2326，1606，1472，1419，1353，1272，1200，1116，1012，940，750；
ESI-MS：440[M+H]
+；
1HNMR (300MHz D
2O) δ (ppm): 2.08～2.19 (m 2H ， isoxazole ring-C-CH
2-C-piperazine ring), 2.16 (s, 3H ， isoxazole ring 3-CH
3), 2.26 (s, 6H, 2 * Ar-CH
3), 2.58 (s, 3H ， oxadiazole ring-CH
3), 2.85 (t, 2H, J=7.2Hz ， isoxazole ring-C-C-CH
2-piperazine ring), 3.28 (t, 2H, J=3Hz ， isoxazole ring-CH
2-C-C-piperazine ring), 3.68 (br, 10H, 8 H on the piperazine ring and piperazine ring-CH
2-C-O-Ar), 4.18 (br, 2H ,-CH
2-O-Ar), 6.11 (s, 1H ， isoxazole ring 4-H), 7.57 (s, 2H, 2 * Ar-H);
Anal.C
24H
33N
5O
3·2HCl Found(％)：C 56.09，H 6.95，N 13.29
Calcd(％)：C 56.25，H 6.88，N 13.67
Embodiment 3
1-[2-[2,6-dimethyl-4-(5-cyclopropyl-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-methyl-isoxazole-5-yl) propyl group] piperazine hydrochloride (IA
5, R
1=R
2=R
3=CH
3, m=2, n=3, R
4=cyclopropyl)
With reference to IA
1(R
1=R
2=R
3=CH
3, m=2, n=3, R
4=CF
3) the preparation method by xii (R
1=R
2=R
3=CH
3, m=2, n=3,0.42g, 0.001mol) (0.13ml 0.0015mol) makes with ring third formyl chloride.[chloroform: (v: v)], get faint yellow oily thing, salify gets shallow khaki color puffy solid to acetone=6: 1 to column chromatography, and yield is 46.4%, mp219-221 ℃.
IR(KCl，cm
-1)：3440，2974，2386，1606，1582，1447，1419，1346，1201，1031，892，766；
ESI-MS：466[M+H]
+，488[M+Na]
+；
1HNMR (500MHz, D
2O), δ (ppm): 1.14～1.40 (m, 4H, the H of two methylene radical on the cyclopropyl), 2.26～2.33 (m, 3H ， isoxazole ring-C-CH
2The H of methyne on-C-piperazine ring and the cyclopropyl), 2.35 (s, 3H, isoxazole ring 3-CH
3), 2.38 (s, 6H, 2 * Ar-CH
3), 2.98 (t, 2H, J=7.1Hz ， isoxazole ring-C-C-CH
2-piperazine ring), 3.44 (t, 2H, J=8Hz ， isoxazole ring-CH
2-C-C-piperazine ring), 3.82～3.88 (br, 10H, 8 H on the piperazine ring and piperazine ring-CH
2-C-O-Ar), 4.31 (br, 2H ,-CH
2-O-Ar), 6.24 (s, 1H ， isoxazole ring 4-H), 7.58 (s, 2H, 2 * Ar-H);
Anal.C
26H
35N
5O
3·2HCl·1.5H
2O Found(％)：C 55.48，H 7.22，N 12.21
Calcd(％)：C 55.22，H 7.13，N 12.38
Embodiment 4
1-[2-[2,6-dimethyl-4-(5-ethyl-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-methyl-isoxazole-5-yl) propyl group] piperazine hydrochloride (IA
7, R
1=R
2=R
3=CH
3, m=2, n=3, R
4=Et)
With reference to IA
1(R
1=R
2=R
3=CH
3, m=2, n=3, R
4=CF
3) the preparation method by xii (R
1=R
2=R
3=CH
3, m=2, n=3,0.42g, 0.001mol) and propionyl chloride (0.13ml 0.0015mol) makes.Column chromatography [chloroform: acetone=6: 1 (v/v)] obtains yellow oil,
1HNMR (300MHz, CDCl
3), δ (ppm): 1.44 (t, 3H, J=7.5Hz oxadiazole ring-C-CH
3), 1.82～1.92 (m, 2H ， isoxazole ring-C-CH
2-C-piperazine ring), 2.25 (s, 3H ， isoxazole ring 3-CH
3), 2.34 (s, 6H, 2 * Ar-CH
3), 2.41 (t, 2H ， isoxazole ring-C-C-CH
2-piperazine ring), 2.52～2.62 (br, 8H, 8 H on the piperazine ring), 2.75 (t2H, J=7.5Hz ， isoxazole ring-CH
2-C-C-piperazine ring), 2.81 (t, 2H, J=5.9Hz, piperazine ring-CH
2-C-O-Ar), 2.91～2.99 (q, 2H ， oxadiazole ring-CH
2-CH
3), 3.93 (t, 2H, J=5.8Hz ,-CH
2-O-Ar), 5.81 (s, 1H ， isoxazole ring 4-H), 7.73 (s, 2H, 2 * Ar-H).
Salify gets white puffy solid, and yield is 66.5%, mp223-225 ℃.
IR(KCl，cm
-1)：3420，2979，2333，1606，1576，1450，1417，1353，1204，1029，989，803；
ESI-MS：454[M+H]
+；
1HNMR (300MHz, D
2O), δ (ppm): 1.33～1.38 (m, 3H ， oxadiazole ring-C-CH
3), 2.13～2.31 (m, 11H ， isoxazole ring-C-CH
2-C-piperazine ring is with isoxazole ring 3-CH
3With 2 * Ar-CH
3), 2.87～2.98 (m, 4H ， isoxazole ring-C-C-CH
2-piperazine ring is with oxadiazole ring-CH
2-CH
3), 3.36 (t, 2H ， isoxazole ring-CH
2-C-C-piperazine ring), 3.75 (br, 10H, 8 H on the piperazine ring and piperazine ring-CH
2-C-O-Ar), 4.24 (s, 2H ,-CH
2-O-Ar), 6.15 (s, 1H ， isoxazole ring 4-H), 7.60 (s, 2H, 2 * Ar-H);
Anal.C
25H
35N
5O
3·2HCl Found(％)：C 57.11，H 6.88，N 13.36
Calcd(％)：C 57.03，H 7.08，N 13.30
Embodiment 5
1-[2-[2,6-dimethyl-4-(5-propyl group-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-methyl-isoxazole-5-yl) propyl group] piperazine hydrochloride (IA
9, R
1=R
2=R
3=CH
3, m=2, n=3, R
4=CH
2CH
2CH
3)
With reference to IA
1(R
1=R
2=R
3=CH
3, m=2, n=3, R
4=CF
3) the preparation method by xii (R
1=R
2=R
3=CH
3, m=2, n=3,0.42g, 0.001mol) and butyryl chloride (0.16ml 0.0015mol) makes.Column chromatography [chloroform: acetone=6: 1 (v: v)], get yellow oil,
1HNMR (300MHz, CDCl
3), δ (ppm): 1.05 (t, 3H, J=7.2Hz ， oxadiazole ring-C-C-CH
3), 1.84～1.94 (m, 4H ， oxadiazole ring-C-CH
2-CH
3He isoxazole ring-C-CH
2-C-piperazine ring), 2.25 (s, 3H ， isoxazole ring 3-CH
3), 2.34 (s, 6H, 2 * Ar-CH
3), 2.42 (t, 2H ， isoxazole ring-C-C-CH
2-piperazine ring), 2.54～2.63 (br, 8H, 8 H on the piperazine ring), 2.75 (t, 2H, J=7.5Hz ， isoxazole ring-CH
2-C-C-piperazine ring), 2.81 (t, 2H, J=6Hz, piperazine ring-CH
2-C-O-Ar), 2.90 (t, 2H, J=7.5Hz ， oxadiazole ring-CH
2-CH
3), 3.94 (t, 2H, J=6Hz ,-CH
2-O-Ar), 5.81 (s, 1H ， isoxazole ring 4-H), 7.73 (s, 2H, 2 * Ar-H)
Salify gets white puffy solid, and yield is 57.4%, mp217-219 ℃.
IR(KCl，cm
-1)：2970，2391，1609，1577，1450，1419，1351，1198，1115，1014，995，755；
ESI-MS：468[M+H]
+；
1HNMR (300MHz, D
2O), δ (ppm): 0.92～0.97 (m, 3H ， oxadiazole ring-C-C-CH
3), 1.74～1.78 (m, 2H ， oxadiazole ring-C-CH
2-CH
3), 2.15～2.25 (m, 11H ， isoxazole ring-C-CH
2-C-piperazine ring is with isoxazole ring 3-CH
3With 2 * Ar-CH
3), 2.87～2.88 (br, 4H ， isoxazole ring-C-C-CH
2-piperazine ring is with oxadiazole ring-CH
2-CH
3), 3.33～3.38 (m, 2H ， isoxazole ring-CH
2-C-C-piperazine ring), 3.76～3.82 (br, 10H, 8 H on the piperazine ring and piperazine ring-CH
2-C-O-Ar), 4.21 (br, 2H-CH
2-O-Ar), 6.13 (s, 1H ， isoxazole ring 4-H), 7.46 (s, 2H, 2 * Ar-H);
Anal.C
26H
37N
5O
3·2HCl Found(％)：C 57.62，H 7.51，N 12.54
Calcd(％)：C 57.77，H 7.27，N 12.96
Embodiment 6
1-[2-[2,6-dimethyl-4-(the 5-tertiary butyl-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-methyl-isoxazole-5-yl) propyl group] piperazine hydrochloride (IA
11, R
1=R
2=R
3=CH
3, m=2, n=3, R
4=C (CH
3)
3)
With reference to IA
1(R
1=R
2=R
3=CH
3, m=2, n=3, R
4=CF
3) the preparation method by xii (R
1=R
2=R
3=CH
3, m=2, n=3,0.3g, 0.00072mol) and pivaloyl chloride (0.13ml 0.0011mol) makes.[chloroform: (v: v)], get yellow oil, salify gets the oyster white tabular crystal to acetone=4: 1 to column chromatography, and yield is 40.1%, mp207-209 ℃.
IR(KCl，cm
-1)：3443，2977，2348，1607，1573，1448，1417，1355，1203，1031，995，780；
ESI-MS：482[M+H]
+；
1HNMR (300MHz D
2O) δ (ppm): 1.38 (s, 9H ， oxadiazole ring-C (CH
3)
3) 2.16～2.23 (m, 11H ， isoxazole ring-C-CH
2-C-piperazine ring is with isoxazole ring 3-CH
3With 2 * Ar-CH
3), 2.89 (t, 2H, J=7.2Hz ， isoxazole ring-C-C-CH
2-piperazine ring), 3.37 (t, 2H, J=8.1Hz ， isoxazole ring-CH
2-C-C-piperazine ring), 3.77～3.85 (br, 10H, 8 H on the piperazine ring and piperazine ring-CH
2-C-O-Ar), 4.20 (br, 2H ,-CH
2-O-Ar), 6.15 (s, 1H ， isoxazole ring 4-H), 7.41 (s, 2H, 2 * Ar-H);
Anal.C
27H
39N
5O
3·2HCl·0.35H
2O Found(％)：C 57.83，H 7.54，N 12.23
Calcd(％)：C 57.82，H 7.49，N 12.49
Embodiment 7
1-[2-[2,6-dimethyl-4-(5-trichloromethyl-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-methyl-isoxazole-5-yl) propyl group] piperazine hydrochloride (IA
13, R
1=R
2=R
3=CH
3, m=2, n=3, R
4=CCl
3)
With reference to IA
1(R
1=R
2=R
3=CH
3, m=2, n=3, R
4=CF
3) the preparation method by xii (R
1=R
2=R
3=CH
3, m=2, n=3,0.1g, 0.00024mol) and trichoroacetic chloride (0.054ml 0.00048mol) makes.[chloroform: (v: v)], get yellow oil, salify gets the canescence tabular crystal to acetone=4: 1 to column chromatography, and yield is 48.1%, mp206-208 ℃.
ESI-MS：542[M+H]
+；
1HNMR (300MHz, D
2O) δ (ppm): 2.14～2.23 (m, 11H ， isoxazole ring-C-CH
2-He isoxazole ring 3-CH
3And 2 * Ar-CH
3), 2.86 (t, 2H ， isoxazole ring-C-C-CH
2-piperazine ring), 3.34 (t, 2H ， isoxazole ring-CH
2-), 3.73-3.79 (br, 10H, 8 H on the piperazine ring and piperazine ring-CH
2-C-O-Ar), 4.20 (br, 2H ,-CH
2-O-Ar), 6.12 (s, 1H ， isoxazole ring 4-H), 7.52 (s, 2H, 2 * Ar-H);
Embodiment 8
(1), 5-(3-chloropropyl)-3-propyl group isoxazole (x, R
1=CH
2CH
2CH
3, n=3)
-be equipped with in the 500ml four-necked bottle of mechanical stirring, dropping funnel, thermometer and reflux condensing tube, adding NCS (12.02g, the dry DMF solution of 144ml 0.09mol) adds 1-2 again and drips pyridine, drip butyraldehyde oxime (8.5ml, the dry DMF solution of 36ml 0.09mol) under the room temperature.Drip and finish, keep 25-30 ℃ of reaction 1h.Add then 5-chloro-1-pentyne (5.3ml, the dry DMF solution of 0.05mol) 40ml is warming up to 85-90 ℃, (12.5ml, the dry DMF solution of 72ml 0.09mol) keeps 85-90 ℃ to react 1.5h to drip triethylamine.After reaction finishes, be chilled to room temperature, add 100ml water, with ethyl acetate (3 * 300ml) extractions merge organic phase, use 10% sal enixum, water, each 150ml of saturated aqueous common salt washes, anhydrous magnesium sulfate drying is concentrated.Underpressure distillation, the cut of collection 113-118 ℃ (4mmHg) gets colourless liquid 8.4g, productive rate 89.6%.
ESI-MS：188[M+H]
+
(2), 3,5-dimethyl-4-[2-[4-[3-(3-propyl group isoxazole-5-base) propyl group] piperazine-1-yl] oxyethyl group] benzene nitrile (xi, R
1=CH
2CH
2CH
3, R
2=R
3=CH
3, m=2, n=3)
With reference to embodiment 1 experimental implementation (6) compound xi (R
1=R
2=R
3=CH
3, m=2, the preparation method of n=310a is by compound viii (R
2=R
3=CH
3, m=2,2.59g is 0.01mol) with compound x (R
1=CH
2CH
2CH
3, n=3,2.06g 0.011mol) makes.Get yellow oil 3.4g, productive rate is 82.9%.Without being further purified direct input the next step.
ESI-MS：411[M+H]
+
(3), N '-hydroxyl-3,5-dimethyl-4-[2-[4-[3-(3-propyl group isoxazole-5-base) propyl group] piperazine-1-yl] oxyethyl group] benzenyl amidine (xii, R
1=CH
2CH
2CH
3, R
2=R
3=CH
3, m=2, n=3)
With reference to embodiment 1 compound xii (R
1=R
2=R
3=CH
3, m=2, preparation method n=3) is by compound xi (R
1=R
2=R
3=CH
3, m=2, n=3,3.6g, 0.0088mol), and oxammonium hydrochloride (3.05g 0.044mol) makes.[chloroform: (v: v)], get yellow oil 2.2g, productive rate is 56.4% to methyl alcohol=10: 1 to column chromatography.
ESI-MS：444[M+H]
+
(4), 1-[2-[2,6-dimethyl-4-(5-Trifluoromethyl-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-propyl group isoxazole-5-base) propyl group] piperazine hydrochloride (IA
2, R
1=CH
2CH
2CH
3, R
2=R
3=CH
3, m=2, n=3, R
4=CF
3)
With reference to IA
1(R
1=R
2=R
3=CH
3, m=2, n=3, R
4=CF
3) the preparation method by xii (R
1=CH
2CH
2CH
3, R
2=R
3=CH
3, m=2, n=3,0.72g, 0.0016mol) and trifluoroacetic anhydride (0.45ml 0.0033mol) makes.[chloroform: (v: v)], get brown oil, salify gets the white powder solid to acetone=4: 1 to column chromatography, and yield is 63.6%, mp211-213 ℃.
IR(KCl，cm
-1)：2967，2349，1605，1467，1375，1320，1208，1160，1109，993，766；
ESI-MS：522[M+H]
+；
1HNMR (300MHz, D
2O), δ (ppm): 0.86 (t, 3H, J=7.4Hz ， isoxazole ring 3-C-C-CH
3), 1.58～1.65 (m, 2H ， isoxazole ring 3-C-CH
2-CH
3), 2.11～2.21 (m, 2H ， isoxazole ring-C-CH
2-C-piperazine ring), 2.32 (s, 6H, 2 * Ar-CH
3), 2.58 (t, 2H, J=7.3Hz ， isoxazole ring-C-C-CH
2-piperazine ring), 2.88 (t, 2H, J=6Hz ， isoxazole ring 3-CH
2-C-CH
3), 3.32 (t, 2H, J=9Hz ， isoxazole ring-CH
2-C-C-piperazine ring), 3.69 (br, 10H, 8 H on the piperazine ring and piperazine ring-CH
2-C-O-Ar), 4.24 (br, 2H ,-CH
2-O-Ar), 6.18 (s, 1H ， isoxazole ring 4-H), 7.76 (s, 2H, 2 * Ar-H);
Anal.C
26H
34N
5O
3F
3·2HCl Found(％)：C 52.42，H 6.04，N 11.64
Calcd(％)：C 52.53，H 6.10，N 11.78
Embodiment 9
1-[2-[2,6-dimethyl-4-(5-methyl isophthalic acid, 2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-propyl group isoxazole-5-base) propyl group] piperazine hydrochloride (IA
4, R
1=CH
2CH
2CH
3, R
2=R
3=R
4=CH
3, m=2, n=3)
With reference to IA
1(R
1=R
2=R
3=CH
3, m=2, n=3, R
4=CF
3) the preparation method by xii (R
1=CH
2CH
2CH
3, R
2=R
3=CH
3, m=2, n=3,0.4g, 0.0009mol) and Acetyl Chloride 98Min. (0.12ml 0.0014mol) makes.[chloroform: (v: v)], get faint yellow oily thing, salify gets shallow light yellow coloured particles shape solid to acetone=4: 1 to column chromatography, and yield is 35.7%, mp205-207 ℃.
IR(KCl，cm
-1)：2965，2328，1583，1447，1352，1270，1200，1113，1009，915，757；
ESI-MS：468[M+H]
+；
1HNMR (300MHz, D
2O), δ (ppm): 0.83 (t, 3H, J=7,2Hz ， isoxazole ring 3-C-C-CH
3), 1.54～1.62 (m, 2H ， isoxazole ring 3-C-CH
2-CH
3), 2.09～2.16 (m, 2H ， isoxazole ring-C-CH
2-C-piperazine ring), 2.26 (s, 6H, 2 * Ar-CH
3), 2.52～2.57 (m, 5H ， oxadiazole ring-CH
3He isoxazole ring-C-C-CH
2-piperazine ring), 2.84 (t, 2H, J=6.9Hz ， isoxazole ring 3-CH
2-C-CH
3), 3.24 (t, 2H ， isoxazole ring-CH
2-C-C-piperazine ring), 3.60 (br, 10H, 8 H on the piperazine ring and piperazine ring-CH
2-C-O-Ar), 4.16 (br, 2H ,-CH
2-O-Ar), 6.13 (s, 1H ， isoxazole ring 4-H), 7.59 (s, 2H, 2 * Ar-H);
Anal.C
26H
37N
5O
3·2HCl Found(％)：C 57.71，H 7.36，N 12.65
Calcd(％)：C 57.77，H 7.27，N 12.96
Embodiment 10
1-[2-[2,6-dimethyl-4-(5-cyclopropyl-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-propyl group isoxazole-5-base) propyl group] piperazine hydrochloride (IA
6, R
1=CH
2CH
2CH
3, R
2=R
3=CH
3, m=2, n=3, R
4=cyclopropyl)
With reference to IA
1(R
1=R
2=R
3=CH
3, m=2, n=3, R
4=CF
3) the preparation method by xii (R
1=CH
2CH
2CH
3, R
2=R
3=CH
3, m=2, n=3,0.35g, 0.0008mol) (0.11ml 0.0012mol) makes with ring third formyl chloride.[chloroform: (v: v)], get yellow oil, salify gets shallow khaki color particulate solid to acetone=6: 1 to column chromatography, and yield is 26.2%, mp200-202 ℃.
IR(KCl，cm
-1)：3400，2962，2327，1769，1712，1580，1448，1379，1203，1088，944，765；
ESI-MS：494[M+H]
+；
1HNMR (300MHz, D
2O), δ (ppm): 0.82 (t, 3H, J=7.5Hz ， isoxazole ring 3-C-C-CH
3), 1.04～1.26 (m, 4H, the H of two methylene radical of cyclopropyl), 1.53～1.58 (m, 2H ， isoxazole ring 3-C-CH
2-CH
3), 2.11～2.25 (m, 9H ， isoxazole ring-C-CH
2-C-piperazine ring and cyclopropyl methyne H and 2 * Ar-CH
3), 2.54 (t, 2H, J=7.4Hz ， isoxazole ring-C-C-CH
2-piperazine ring), 2.82 (t, 2H, J=3Hz ， isoxazole ring 3-CH
2-C-CH
3), 3.25 (t, 2H ， isoxazole ring-CH
2-C-C-piperazine ring), 3.61 (br, 10H, 8 H on the piperazine ring and piperazine ring-CH
2-C-O-Ar), 4.16 (br, 2H ,-CH
2-O-Ar), 6.13 (s, 1H ， isoxazole ring 4-H), 7.54 (s, 2H, 2 * Ar-H);
Anal.C
28H
39N
5O
3·2HCl·0.4H
2O·1.1CH
3CH
2OH
Found(％)：C 58.03，H 7.53，N 11.21
Calcd(％)：C 58.09，H 7.81，N 11.22
Embodiment 11
1-[2-[2,6-dimethyl-4-(5-ethyl-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-propyl group isoxazole-5-base) propyl group] piperazine hydrochloride (IA
8, R
1=CH
2CH
2CH
3, R
2=R
3=CH
3, m=2, n=3, R
4=Et)
With reference to IA
1(R
1=R
2=R
3=CH
3, m=2, n=3, R
4=CF
3) the preparation method by xii (R
1=CH
2CH
2CH
3, R
2=R
3=CH
3, m=2, n=3,0.3g, 0.00068mol) and propionyl chloride (0.09ml 0.001mol) makes.[chloroform: (v: v)], get yellow oil, salify gets yellow powder powder solid to acetone=6: 1 to column chromatography, and yield is 26.5%, mp193-195 ℃.
IR(KCl，cm
-1)：3443，2966，2347，1604，1579，1422，1374，1199，1116，1029，940，797；
ESI-MS：482[M+H]
+；
1HNMR (300MHz, D
2O), δ (ppm): 0.87 (t, 3H, J=7.2Hz ， isoxazole ring 3-C-C-CH
3), 1.33 (t, 3H, J=7.2Hz ， oxadiazole ring-C-CH
3), 1.56～1.65 (q, 2H ， isoxazole ring 3-C-CH
2-CH
3), 2.16～2.27 (m, 8H ， isoxazole ring-C-CH
2-C-piperazine ring and 2 * Ar-CH
3), 2.58 (t, 2H, J=7.2Hz ， isoxazole ring-C-C-CH
2-piperazine ring) 2.87～2.97 (m, 4H ， oxadiazole ring-CH
2-CH
3He isoxazole ring 3-CH
2-C-CH
3), 3.35 (t, 2H, J=7.8Hz ， isoxazole ring-CH
2-C-C-piperazine ring), 3.74～3.80 (br, 10H, 8 H on the piperazine ring and piperazine ring-CH
2-C-O-Ar), 4.22 (br, 2H ,-CH
2-O-Ar), 6.18 (s, 1H ， isoxazole ring 4-H), 7.51 (s, 2H, 2 * Ar-H);
Anal.C
27H
39N
5O
3·2HCl·0.4H
2O Found(％)：C 57.72，H 7.65，N 12.05
Calcd(％)：C 57.73，H 7.50，N 12.47
Embodiment 12
1-[2-[2,6-dimethyl-4-(5-propyl group-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-propyl group isoxazole-5-base) propyl group] piperazine hydrochloride (IA
10, R
1=CH
2CH
2CH
3, R
2=R
3=CH
3, m=2, n=3, R
4=CH
3CH
2CH
2)
With reference to IA
1(R
1=R
2=R
3=CH
3, m=2, n=3, R
4=CF
3) the preparation method by xii (R
1=CH
2CH
2CH
3, R
2=R
3=CH
3, m=2, n=3,0.7g, 0.0016mol) and butyryl chloride (0.25ml 0.0024mol) makes.[chloroform: (v: v)], get faint yellow oily thing, salify gets yellow powder powder solid to acetone=6: 1 to column chromatography, and yield is 41.8%, mp199-201 ℃.
IR(KCl，cm
-1)：2964，2324，1604，1576，1452，1421，1374，1198，1091，1031，891，767；
ESI-MS：496[M+H]
+；
1HNMR (300MHz D
2O) δ (ppm): 0.81～0.94 (m, 6H ， isoxazole ring 3-C-C-CH
3He oxadiazole ring-C-C-CH
3), 1.54～1.62 (q, 2H ， isoxazole ring 3-C-CH
2-CH
3), 1.72～1.79 (q, 2H ， oxadiazole ring-C-CH
2-CH
3), 2.15～2.24 (m, 8H ， isoxazole ring-C-CH
2-C-piperazine ring and 2 * Ar-CH
2) 2.54 (t, 2H, J=7.2Hz ， isoxazole ring-C-C-CH
2-piperazine ring), 2.86 (br, 4H ， oxadiazole ring-CH
2-C-CH
3And isoxazole ring 3-CH
2-C-CH
3), 3.31 (t, 2H ， isoxazole ring-CH
2-C-C-piperazine ring), 3.70～3.76 (br, 10H, 8 H on the piperazine ring and piperazine ring-CH
2-C-O-Ar), 4.19 (br, 2H ,-CH
2-O-Ar), 6.15 (s, 1H ， isoxazole ring 4-H), 7.51 (s, 2H, 2 * Ar-H);
Anal.C
28H
41N
5O
3·2HCl Found(％)：C 58.87，H 7.72，N 12.00
Calcd(％)：C 59.15，H 7.62，N 12.32
Embodiment 13
1-[2-[2,6-dimethyl-4-(the 5-tertiary butyl-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-propyl group isoxazole-5-base) propyl group] piperazine hydrochloride (IA
12, R
1=CH
2CH
2CH
3, R
2=R
3=CH
3, m=2, n=3, R
4=C (CH
3)
3)
With reference to IA
1(R
1=R
2=R
3=CH
3, m=2, n=3, R
4=CF
3) the preparation method by xii (R
1=CH
2CH
2CH
3, R
2=R
3=CH
3, m=2, n=3,0.3g, 0.00068mol) and pivaloyl chloride (0.12ml 0.001mol) makes.[chloroform: (v: v)], get yellow oil, salify gets yellow powder powder solid to acetone=4: 1 to column chromatography, and yield is 20.2%, mp201-203 ℃.
IR(KCl，cm
-1)：3442，2973，2380，1605，1573，1461，1422，1354，1201，1112，1030，781；
ESI-MS：510[M+H]
+；
1HNMR (300MHz, D
2O), δ (ppm): 0.89 (t, 3H, J=7.2Hz ， isoxazole ring 3-C-C-CH
3), 1.45 (s, 9H ， oxadiazole ring-C (CH
3)
3), 1.64 (m, 2H ， isoxazole ring 3-C-CH
2-CH
3), 2.20 (t, 2H ， isoxazole ring-C-CH
2-C-piperazine ring), 2.32 (s, 6H, 2 * Ar-CH
3), 2.61 (t, 2H, J=7.2Hz ， isoxazole ring-C-C-CH
2-piperazine ring) 2.90 (t, 2H ， isoxazole ring 3-CH
2-C-CH
3), 3.37 (br, 2H ， isoxazole ring-CH
2-C-C-piperazine ring), 3.77～3.83 (br, 10H, 8 H on the piperazine ring and piperazine ring-CH
2-C-O-Ar), 4.26 (s, 2H ,-CH
2-O-Ar), 6.21 (s, 1H ， isoxazole ring 4-H), 7.63 (s, 2H, 2 * Ar-H);
Anal.C
29H
43N
5O
3·2HCl·0.25H
2O Found(％)：C 59.32，H 7.72，N 11.57
Calcd(％)：C 59.32，H 7.81，N 11.93
Embodiment 14
1-[2-[2,6-dimethyl-4-(5-trichloromethyl-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-propyl group isoxazole-5-base) propyl group] piperazine hydrochloride (IA
14, R
1=CH
2CH
2CH
3, R
2=R
3=CH
3, m=2, n=3, R
4=CCl
3)
With reference to IA
1(R
1=R
2=R
3=CH
3, m=2, n=3, R
4=CF
3) the preparation method by xii (R
1=CH
2CH
2CH
3, R
2=R
3=CH
3, m=2, n=3,0.1g, 0.0023mol) and trichoroacetic chloride (0.05ml 0.0045mol) makes.[chloroform: (v: v)], get brown oil, salify gets the white powder solid to acetone=4: 1 to column chromatography, and yield is 34.6%, mp210-212 ℃.
ESI-MS：570[M+H]
+；
1HNMR (300MHz, D
2O), δ (ppm): 0.89 (t, 3H, J=7.4Hz ， isoxazole ring 3-C-C-CH
3), 1.6～1.68 (m, 2H ， isoxazole ring 3-C-CH
2-CH
3), 2.19 (m, 2H ， isoxazole ring-C-CH
2-C-piperazine ring), 2.35 (s, 6H, 2 * Ar-CH
3), 2.61 (t, 2H ， isoxazole ring-C-C-CH
2-piperazine ring), 2.91 (t, 2H ， isoxazole ring 3-CH
2-C-CH
3), 3.35 (t, 2H ， isoxazole ring-CH
2-C-C-piperazine ring) 3.75-3.80 (br, 10H, 8 H on the piperazine ring and piperazine ring-CH
2-C-O-Ar), 4.28 (br, 2H ,-CH
2-O-Ar), 6.20 (s, 1H ， isoxazole ring 4-H), 7.78 (s, 2H, 2 * Ar-H).
Claims (21)
1, the compound or pharmaceutically acceptable salt thereof of structural formula as I:
In the structural formula:
R
1Be alkyl, alkoxyl group, hydroxyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl, hydroxyl alkoxyl group, alkane sulfane base, alkyl sulfenyl alkyl, alkyl sulfonyl alkyl, aminoalkyl group, alkyl-substituted amino alkyl, dialkyl group substituted-amino alkyl, alkoxycarbonyl, carboxyl or cyanogen methyl;
R
2And R
3Be respectively hydrogen, alkyl, alkoxyl group, halogen, cyano group, trifluoromethyl or nitro;
R
4Be alkyl, alkoxyl group, hydroxyl, monochloromethyl, dihalomethyl, trihalogenmethyl, two haloethyls, cycloalkyl, heterocycle, alkoxycarbonyl, hydroxyalkyl, alkoxyalkyl, alkyl carboxylic oxyalkyl, cyano group, halogen, alkylthio, alkane sulfane base, alkylthio, sulfydryl, 2,2,2-trifluoroethyl, (4-methyl-phenyl) sulphonyl oxygen methyl, amino, alkyl-substituted amino, dialkyl group substituted-amino, amido or N-alkyl replace amido;
R
5Be hydrogen, halogen or alkyl;
X is O or S;
Y is oxygen, sulphur, NR
6, pyrroles, pyridine, imidazoles, tetramethyleneimine, imidazolidine, piperidines, piperazine or morpholine; The R here
6Be alkyl, acyl group, aralkyl, aroyl or alkylsulfonyl;
N is 0-5;
M is 0-5.
2, according to the compound of claim 1, wherein
R
1Be C
1-5Alkyl, hydroxyl-C
1-5Alkyl, C
1-3Alkoxy-C
1-5Alkyl, first thiomethyl, methyl sulfinyl methyl, methylsulfonyl methyl, amino-C
1-5Alkyl, C
1-3Alkylamino-C
1-5Alkyl, C
1-3Dialkyl amido-C
1-5Alkyl, C
1-5Alkoxycarbonyl, carboxyl or cyanogen methyl.
3, according to the compound of claim 1, wherein
R
1Be methyl, ethyl, n-propyl, sec.-propyl or cyclopropyl.
4, according to the compound of claim 1, wherein
R
2And R
3Be respectively C
1-5Alkyl, halogen, cyano group, trifluoromethyl or nitro.
5, according to the compound of claim 4, wherein
R
2And R
3Be respectively methyl, chlorine, bromine or fluorine.
6, according to the compound of claim 1, wherein
R
4Be C
1-3Alkyl or trihalogenmethyl.
7, according to the compound of claim 1, wherein
R
4Be methyl, ethyl, n-propyl, sec.-propyl, cyclopropyl, trichloromethyl or trifluoromethyl.
8, according to the compound of claim 1, wherein
R
5Be hydrogen, halogen or C
1-5Alkyl.
9, according to the compound of claim 1, wherein
X is O.
10, according to the compound of claim 1, wherein
R
6Be C
1-8Alkyl, acyl group, benzyl, aroyl or alkylsulfonyl.
11, according to the compound of claim 1, wherein
Y is pyrroles, pyridine, imidazoles, tetramethyleneimine, imidazolidine, piperidines, piperazine or morpholine.
12, according to the compound of claim 1, wherein
M is 1-3;
N is 1-3.
13, according to the compound or pharmaceutically acceptable salt thereof of claim 1, compound in structural formula I forms pharmacologically acceptable salts with the acid that proton can be provided, and these acid are mineral acid or organic acid.
14, according to the compound or pharmaceutically acceptable salt thereof of claim 13, wherein
Mineral acid is hydrochloric acid, Hydrogen bromide, hydroiodic acid HI, sulfuric acid, phosphoric acid or nitric acid; Organic acid is saturated fatty acid, the C of 1～10 carbon atom
1-4The unsaturated fatty acids of alkylsulphonic acid, 4～20 carbon atoms or aromatic acid.
15, according to the compound or pharmaceutically acceptable salt thereof of claim 13, wherein
Organic acid is formic acid, acetate, propionic acid, butyric acid, valeric acid, caproic acid, fumaric acid, toxilic acid, succsinic acid, tartrate, phenylformic acid, Phenylsulfonic acid or tosic acid.
16, according to the compound or pharmaceutically acceptable salt thereof of claim 1, it is selected from:
1-[2-[2,6-dimethyl-4-(5-Trifluoromethyl-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-methyl-isoxazole-5-yl) propyl group] piperazine or its pharmaceutical salts;
1-[2-[2,6-dimethyl-4-(5-Trifluoromethyl-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-propyl group isoxazole-5-base) propyl group] piperazine or its pharmaceutical salts;
1-[2-[2,6-dimethyl-4-(5-methyl isophthalic acid, 2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-methyl-isoxazole-5-yl) propyl group] piperazine or its pharmaceutical salts;
1-[2-[2,6-dimethyl-4-(5-methyl isophthalic acid, 2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-propyl group isoxazole-5-base) propyl group] piperazine or its pharmaceutical salts;
1-[2-[2,6-dimethyl-4-(5-cyclopropyl-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-methyl-isoxazole-5-yl) propyl group] piperazine or its pharmaceutical salts;
1-[2-[2,6-dimethyl-4-(5-cyclopropyl-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-propyl group isoxazole-5-base) propyl group] piperazine or its pharmaceutical salts;
1-[2-[2,6-dimethyl-4-(5-ethyl-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-methyl-isoxazole-5-yl) propyl group] piperazine or its pharmaceutical salts;
1-[2-[2,6-dimethyl-4-(5-ethyl-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-propyl group isoxazole-5-base) propyl group] piperazine or its pharmaceutical salts;
1-[2-[2,6-dimethyl-4-(5-propyl group-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-methyl-isoxazole-5-yl) propyl group] piperazine or its pharmaceutical salts;
1-[2-[2,6-dimethyl-4-(5-propyl group-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-propyl group isoxazole-5-base) propyl group] piperazine or its pharmaceutical salts;
1-[2-[2,6-dimethyl-4-(the 5-tertiary butyl-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-methyl-isoxazole-5-yl) propyl group] piperazine or its pharmaceutical salts;
1-[2-[2,6-dimethyl-4-(the 5-tertiary butyl-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-propyl group isoxazole-5-base) propyl group] piperazine or its pharmaceutical salts;
1-[2-[2,6-dimethyl-4-(5-trichloromethyl-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-methyl-isoxazole-5-yl) propyl group] piperazine or its pharmaceutical salts;
1-[2-[2,6-dimethyl-4-(5-trichloromethyl-1,2,4-oxadiazole-3-yl) phenoxy group] ethyl]-4-[3-(3-propyl group isoxazole-5-base) propyl group] piperazine or its pharmaceutical salts.
17, the preparation method of formula IA compound:
R
1, R
2, R
3, R
4Identical with the definition of m and n with the definition in the claim 1.
18, preparation method according to claim 17, wherein the preparation method of intermediate xi is as follows:
R
1, R
2, R
3Identical with the definition of m and n with the definition in the claim 1.
19, preparation method according to claim 17, wherein intermediate xi adopts following preparation method:
R
1, R
2, R
3Identical with the definition of m and n with the definition in the claim 1.
20, the application of claim 1 compound in the medicine that preparation treatment picornavirus infects.
21, the application of claim 1 compound in the medicine of preparation treatment rhinovirus infection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200510039135XA CN100360523C (en) | 2005-04-28 | 2005-04-28 | 1,2,4 furodazole-phenoxyalkyl substituted derivative of iso-oxazole, preparation method and anti virus application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200510039135XA CN100360523C (en) | 2005-04-28 | 2005-04-28 | 1,2,4 furodazole-phenoxyalkyl substituted derivative of iso-oxazole, preparation method and anti virus application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1687060A CN1687060A (en) | 2005-10-26 |
| CN100360523C true CN100360523C (en) | 2008-01-09 |
Family
ID=35305102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200510039135XA Active CN100360523C (en) | 2005-04-28 | 2005-04-28 | 1,2,4 furodazole-phenoxyalkyl substituted derivative of iso-oxazole, preparation method and anti virus application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100360523C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| CN103102348B (en) * | 2011-11-14 | 2016-06-08 | 上海交通大学 | Diazoles compound and preparation method thereof, medical composition and its use |
| CN106018358B (en) * | 2016-05-15 | 2018-09-14 | 马鞍山金安环境科技有限公司 | It is a kind of to detect picric fluorescent optical sensor and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0687857A (en) * | 1992-07-02 | 1994-03-29 | Sterling Winthrop Inc | Heterocyclyl phenoxyalkylpiperidinylpyridazines as antiviral medicines |
| CN1138858A (en) * | 1994-01-17 | 1996-12-25 | 拜尔公司 | 1,2,4-oxadiazole derivatives and their use as parasiticides for animals |
| WO2000078726A1 (en) * | 1999-06-18 | 2000-12-28 | Eli Lilly And Company | Imidazoline derivatives for the treatment of diabetes, especially type ii diabetes |
| CN1445219A (en) * | 2003-04-17 | 2003-10-01 | 浙江大学 | 1,2,4-oxdiazoline containing substituent of aryl group in 3 position and its solid phase synthesis method |
-
2005
- 2005-04-28 CN CNB200510039135XA patent/CN100360523C/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0687857A (en) * | 1992-07-02 | 1994-03-29 | Sterling Winthrop Inc | Heterocyclyl phenoxyalkylpiperidinylpyridazines as antiviral medicines |
| CN1138858A (en) * | 1994-01-17 | 1996-12-25 | 拜尔公司 | 1,2,4-oxadiazole derivatives and their use as parasiticides for animals |
| WO2000078726A1 (en) * | 1999-06-18 | 2000-12-28 | Eli Lilly And Company | Imidazoline derivatives for the treatment of diabetes, especially type ii diabetes |
| CN1445219A (en) * | 2003-04-17 | 2003-10-01 | 浙江大学 | 1,2,4-oxdiazoline containing substituent of aryl group in 3 position and its solid phase synthesis method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1687060A (en) | 2005-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6272221B2 (en) | Inhibitors of viral replication, methods for their preparation and their use in therapy | |
| JP5871401B2 (en) | 2-Arylimidazo [1,2-a] pyridine-3-acetamido derivatives, their preparation and use | |
| US5994353A (en) | Aromatic compounds and pharmaceutical compositions containing them | |
| CN101772487B (en) | Thyroid compounds | |
| JP7461927B2 (en) | A novel series of substituted 3H-imidazo[4,5-c]pyridines and 1H-pyrrolo[2,3-c]pyridines as cancer immunotherapeutic agents and stimulator of interferon genes (STING) modulators | |
| JPWO2005115993A1 (en) | Quinazoline derivatives | |
| JP2007500720A5 (en) | ||
| EP2354136B1 (en) | Novel dopamine d3 receptor ligands and preparation and medical uses of the same | |
| JPWO2005077905A1 (en) | Fused ring 4-oxo-pyrimidine derivatives | |
| CN101952273A (en) | Process for preparation of 2-methyl-2'-phenylpropionic acid derivatives and novel intermediate compounds | |
| JP6413032B2 (en) | Novel DGAT2 inhibitor | |
| JPWO2007049798A1 (en) | New benzooxathiin derivatives | |
| WO2020015669A1 (en) | Anti-influenza virus tricyclic derivative | |
| JP2020506192A (en) | Piperazine derivatives for inhibiting influenza virus | |
| JP4575918B2 (en) | Process for producing 4-allyl-nicotinamide derivatives | |
| EP2655350A1 (en) | Bicyclic pkm2 activators | |
| CN100360523C (en) | 1,2,4 furodazole-phenoxyalkyl substituted derivative of iso-oxazole, preparation method and anti virus application | |
| JP2007261945A (en) | Thiazole derivative | |
| JP2012505165A5 (en) | ||
| EP2350039A1 (en) | Viral polymerase inhibitors | |
| CN1088459C (en) | 1,4-disubstituted piperazines | |
| RU2005131937A (en) | MACROLIDE CONJUGATES, WITH ANTI-INFLAMMATORY ACTIVITY | |
| CN103539659A (en) | 2,4-dibenzyloxybenzoic acid derivative and preparation method and application thereof | |
| JP5964965B2 (en) | Substituted heterocyclic amine compounds as cholesteryl ester transfer protein (CETP) inhibitors | |
| JPH04154773A (en) | Thiazole derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210510 Address after: 215000 Building 8, No.2, South Dongwu Road, Wuzhong Economic Development Zone, Suzhou City, Jiangsu Province Patentee after: JIANGSU WUZHONG PHARMACEUTICAL Group Corp. Patentee after: JIANGSU WUZHONG PHARMACEUTICAL DEVELOPMENT Co.,Ltd. Address before: 210009 10-13 / F, No.26 Majia street, Gulou District, Nanjing City, Jiangsu Province Patentee before: JIANGSU WUZHONG PHARMACEUTICAL DEVELOPMENT Co.,Ltd. |
|
| TR01 | Transfer of patent right |